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A bs tr ac t
Background
Data are lacking on whether lenalidomide maintenance therapy prolongs the time to 
disease progression after autologous hematopoietic stem-cell transplantation in pa-
tients with multiple myeloma.
Methods
Between April 2005 and July 2009, we randomly assigned 460 patients who were 
younger than 71 years of age and had stable disease or a marginal, partial, or com-
plete response 100 days after undergoing stem-cell transplantation to lenalidomide 
or placebo, which was administered until disease progression. The starting dose of 
lenalidomide was 10 mg per day (range, 5 to 15).
Results
The study-drug assignments were unblinded in 2009, when a planned interim analysis 
showed a significantly longer time to disease progression in the lenalidomide group. 
At unblinding, 20% of patients who received lenalidomide and 44% of patients who 
received placebo had progressive disease or had died (P<0.001); of the remaining 
128 patients who received placebo and who did not have progressive disease, 86 
crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients 
who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) 
had disease progression or had died. The median time to progression was 46 months 
in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 
35 patients who received lenalidomide (15%) and 53 patients who received placebo 
(23%) died (P = 0.03). More grade 3 or 4 hematologic adverse events and grade 3 non-
hematologic adverse events occurred in patients who received lenalidomide (P<0.001 
for both comparisons). Second primary cancers occurred in 18 patients who re-
ceived lenalidomide (8%) and 6 patients who received placebo (3%).
Conclusions
Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-
cell transplantation, was associated with more toxicity and second cancers but a 
significantly longer time to disease progression and significantly improved overall 
survival among patients with myeloma. (Funded by the National Cancer Institute; 
ClinicalTrials.gov number, NCT00114101.)
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 18, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Lenalidomide after tr ansplantation for Myeloma
n engl j med 366;19 nejm.org may 10, 2012 1771
A goal of therapy for multiple mye­loma, to induce complete remission and prolong survival, is usually accomplished 
with combination therapy.1,2 Autologous hema-
topoietic stem-cell transplantation is often used 
after induction chemotherapy to improve the re-
sponse or to consolidate complete remission.1,2 
However, since most patients with multiple my-
eloma have disease recurrence or progression after 
transplantation, maintenance therapies have been 
used to prolong complete remission and prevent 
relapse or progressive disease. Low-dose melpha-
lan, interferon alfa, and glucocorticoids have been 
used for maintenance after primary therapy, but 
their long-term use is limited by toxicity and 
modest efficacy.3­6
Five studies involving patients who had under-
gone autologous hematopoietic stem-cell trans-
plantation showed that thalidomide maintenance 
therapy improved progression-free survival, and 
three of the five studies showed improved overall 
survival.7­11 However, long-term thalidomide use is 
limited by toxicity. A sixth study showed no benefit 
with respect to progression-free survival or overall 
survival, but 77% of the patients did not complete 
maintenance therapy.12 Lenalidomide (Revlimid, 
Celgene), an orally administered, immune-modu-
lating drug, has several mechanisms of action 
against multiple myeloma.13 It is an appealing 
agent for long-term use because of its activity when 
used alone at doses lower than induction doses 
and its favorable toxicity profile.14 We designed a 
phase 3, randomized, double-blind, placebo-
controlled trial to determine whether lenalido-
mide therapy would prolong the time to disease 
progression in patients with multiple myeloma 
who had undergone induction therapy and a 
single stem-cell transplantation. Secondary end 
points included overall survival, the response 




Patients were eligible to participate in the trial if 
they had multiple myeloma and were 18 to 70 years 
of age. Other criteria were an Eastern Cooperative 
Oncology Group performance status15 of 0 or 1 (on 
a scale of 0 to 5, with 0 indicating that the patient 
is fully active and 1 indicating that the patient is 
restricted in physically strenuous activity but am-
bulatory and able to carry out work of a light or 
sedentary nature), symptomatic disease requiring 
treatment (Durie–Salmon stage ≥I) (for definitions 
of the stages, see the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org), and any induction regimen of 2 to 12 months’ 
duration. At most, two induction regimens (ex-
cluding dexamethasone alone) could have been 
received.
Patients with stable disease or a marginal, par-
tial, or complete response in the first 100 days 
after stem-cell transplantation were eligible. The 
minimum number of peripheral-blood stem cells 
(CD34+ cells) for transplantation was 2×106 per 
kilogram of body weight. Initially, the protocol 
mandated peripheral-blood stem-cell mobilization 
with cyclophosphamide and granulocyte colony-
stimulating factor within 42 days before transplan-
tation, but the protocol was subsequently amended 
to allow any mobilization and collection at any 
time before transplantation. Adequate pulmonary, 
cardiac, renal, and hepatic function was required, 
and all patients were registered before transplan-
tation. Serious coexisting conditions, including 
uncontrolled diabetes, serious infections, and im-
mune dysfunction, were exclusion criteria; preg-
nancy was also an exclusion criterion, and patients 
participated in an informational program regard-
ing the unknown teratogenic potential of lenalid-
omide. 
After disease restaging, patients were randomly 
assigned in a blinded manner to lenalidomide or 
placebo between day 100 and day 110 after trans-
plantation. All patients provided written informed 
consent. The study was approved by the Cancer 
and Leukemia Group B (CALGB), the Cancer 
Therapy Evaluation Program of the National Can-
cer Institute (NCI), and the NCI central institu-
tional review board.
Study Treatment and Oversight
The dosing schedule and adjustments, as well as 
guidelines for anticoagulation, are described in the 
Supplementary Appendix. The full protocol, along 
with the statistical analysis plan, is available at 
NEJM.org.
The NCI sponsored the study. Celgene provided 
the lenalidomide and placebo to the NCI, which 
in turn provided the study drugs to the investiga-
tors. Celgene had no involvement in the study de-
sign or conduct of the study or in the analysis or 
reporting of the data. The study principal inves-
tigator and the members of the statistical center 
vouch for the accuracy and completeness of the 
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analysis and the data as reported by the site inves-
tigators. The site investigators agreed to participate 
in this study as members of their respective coop-
erative groups and are responsible for the com-
pleteness of data reporting and the fidelity of 
the study to the protocol.
End Points and Definitions
The primary end point was time to progression, 
defined as time to progressive disease or death 
from any cause after transplantation. Response and 
progression were defined initially according to the 
criteria of the European Blood and Marrow Trans-









Median 59 58 59
Range 29–71 40–71 29–71
Male sex — no. 121 129 250
β2-microglobulin at registration — no. (%)
>2.5 mg/liter 50 (22) 55 (24) 105 (23)
≤2.5 mg/liter 170 (74) 163 (71) 333 (72)
Data missing 11 (5) 11 (5) 22 (5)
Durie–Salmon stage at registration — no. (%)†
I 35 (15) 28 (12) 63 (14)
II 71 (31) 59 (26) 130 (28)
III 112 (48) 129 (56) 241 (52)
Data missing 13 (6) 13 (6) 26 (6)
M component — no. (%)
Serum
IgG kappa 70 (30) 76 (33) 146 (32)
IgG lambda 43 (19) 31 (14) 74 (16)
IgA kappa 21 (9) 20 (9) 41 (9)
IgA lambda 13 (6) 13 (6) 26 (6)
IgM kappa 2 (1) 1 (<1) 3 (1)
IgM lambda 0 1 (<1) 1 (<1)
Urine
Kappa light chain only 13 (6) 12 (5) 24 (5)
Lambda light chain only 4 (2) 10 (4) 14 (3)
Data missing 35 (15) 41 (18) 76 (17)
Nonsecretory myeloma — no. (%) 30 (13) 24 (10) 54 (12)
Serum calcium at registration —  mg/dl
Median 9.1 9.1 9.1
Range 7.2–12.8 3.1–10.8 7.2–12.8
Serum albumin at registration — g/dl
Median 4.0 3.9 4.0
Range 1.4–4.9 2.9–5.0 1.4–5.0
Serum creatinine at registration — mg/dl
Median 0.9 0.9 0.9
Range 0.4–1.9 0.5–2.2 0.4–2.2
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plant Group16; these definitions were subsequent-
ly changed to be consistent with the criteria of the 
International Myeloma Working Group17 (see the 
Supplementary Appendix for details).
Statistical Analysis
The primary statistical hypothesis was that the 
time to progression was stochastically longer in 









ISS stage at registration — no. (%)†
I 177 (77) 170 (74) 347 (75)
II 11 (5) 16 (7) 26 (6)
III 4 (2) 3 (1)  7 (2)
Data missing 39 (17) 40 (17)  79 (17)
Induction regimen — no.
Any use of bortezomib 98 91 189 (41)
Any use of lenalidomide 79 81 160 (35)
Any use of thalidomide 102 103 205 (45)
Bortezomib–lenalidomide‡ 20 21 41 (9)
Bortezomib–thalidomide‡ 33 27  60 (13)
Bortezomib without lenalidomide or thalidomide 43 40  83 (18)
Bortezomib with glucocorticoids, without lenalidomide  
or thalidomide
40 32  72 (16)
Bortezomib with lenalidomide and thalidomide 2 3  5 (1)
Lenalidomide without bortezomib 57 57 114 (25)
Thalidomide without bortezomib 67 72 139 (30)
Lenalidomide–glucocorticoids without bortezomib 56 56 112 (24)
Thalidomide–glucocorticoids without bortezomib 65 72 137 (30)
Other induction regimen without bortezomib, lenalidomide,  
or thalidomide
15 13 28 (6)
Other induction regimen not determined 0 1   1 (<1)
Response to autologous HSCT at day 100 — no. (%)
Complete response 67 (29) 79 (34) 146 (32)
Partial response 115 (50) 109 (48) 224 (49)
Marginal response 11 (5) 5 (2) 16 (3)
Stable disease 38 (16) 32 (14)  70 (15)
Progressive disease 0 3 (1)  3 (1)
Data missing 0 1 (<1)   1 (<1)
Mean time from autologous HSCT to randomization — mo 3.3 3.3
* The first patient was enrolled in April 2005, and the study was closed to enrollment in July 2009. To convert the values 
for serum β2-microglobulin to nanomoles per liter, multiply by 84.75. To convert the values for calcium to millimoles 
per liter, multiply by 0.250. To convert the values for creatinine to micromoles per liter, multiply by 88.4. There were no 
significant differences (P<0.05) between the lenalidomide and placebo groups with respect to baseline characteristics. 
There was an overlap in the induction regimens, so percentages may sum to more than 100%. HSCT denotes hemato-
poietic stem-cell transplantation, and ISS International Staging System.
† Higher stages indicate more severe disease. The staging criteria are defined in the Supplementary Appendix.
‡ Patients who received this regimen received at least these two drugs.
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The study was designed to have 90% power, with 
the use of the log-rank test at a one-sided sig-
nificance level of 0.05, to detect a hazard ratio of 
1.4, assuming proportional hazards and an expo-
nential time-to-event distribution. Under the as-
sumed framework, 309 events were expected. The 
expected dropout rate before randomization was 
15%. Of 568 patients registered from 47 centers, 
460 were randomly assigned to a study group with 
the use of a permuted-block design, stratified ac-
cording to three baseline factors: normal or elevat-
ed serum β2-microglobulin level at registration 
(≤2.5 mg per liter vs. >2.5 mg per liter [≤211.9 nmol 
per liter vs. >211.9 nmol per liter]), prior use or 
nonuse of thalidomide during induction therapy; 
and prior use or nonuse of lenalidomide during 
induction therapy. The time-to-progression end 
point was monitored with the use of a group-
sequential design for superiority and futility. In-
terim analyses of time to progression, overall 
survival, and adverse events were presented to the 
data and safety monitoring board of the CALGB 
twice a year when more than 20% of the expected 
events had occurred.
The data were released to the study team on 
December 17, 2009, after the third review because 
statistical evidence favored the lenalidomide group; 
this finding was observed after the first report 
to the data and safety monitoring board in June 
2009. The analyses were based on the intention-
to-treat principle and included follow-up data 
submitted on or before December 17, 2009 (the 
unblinding date) or follow-up data submitted as 
of October 31, 2011 (for evaluation of long-term 
outcomes). To assess the occurrence of second 
primary cancers reported after randomization, 
the nonprotocol end point of event-free survival, 
defined as time to first event (second primary can-
cer, progressive disease, or death) was considered. 
Starting in December 2010, the statistical center 
sent three sets of queries to all participating sites, 
and specific questionnaires were sent to all centers 
regarding cancer screening and second primary 
cancers. The last screening was conducted on Janu-
ary 1, 2012, and no new cases had been reported 
since the October 31, 2011, data analysis.
Survival functions were estimated with the use 
of the Kaplan–Meier method.18 Discrepancies be-
tween survival functions were estimated with the 
use of the hazard ratios from a Cox model,19 un-
der the implicit assumption of proportional haz-
ards. To assess the predictive value of baseline co-
variables, a two-way multiplicative Cox model19 
was used. To assess cause-specific risk (progres-
sion, death, and second primary cancers), the cu-
mulative incidence curves were estimated with the 
use of the Kaplan–Meier method20 and compared 
with the use of the log-rank test proposed by 
Gray.21 All analyses were right-censored since not 
all events had occurred at the time of the analysis, 
and as specified by the protocol, the date of trans-
plantation was used as the reference date. The 
differences between proportions of patients with 
adverse events were tested with the use of Fisher’s 
exact test22 and estimated with the use of a condi-
tional maximum-likelihood estimator of the odds 
ratio.22 Asymptotic P values of less than 10−3 were 
denoted as P<0.001. The analyses were conducted 
with R Statistical Environment software, version 
2.14.1 (R Development Core Team 2011) along with 
survival and cmprsk extension packages. A detailed 
description of statistical considerations, including 
methods of design and analysis, is available in the 
Supplementary Appendix.
R esult s
Characteristics of the Patients
Of the 568 patients enrolled in the study, 460 were 
randomly assigned to a study group: 231 to the 
lenalidomide group and 229 to the placebo group. 
(Fig. S1a and S1b in the Supplementary Appendix 
provide detailed information on the numbers of 
patients who were enrolled, assigned to a study 
group, and included in follow-up.) Age, sex, dis-
ease stage, and serum β2-microglobulin level at 
registration were evenly distributed in the two 
groups (Table 1). Cytogenetic analysis was not 
required. The majority of patients received induc-
tion therapy with a regimen containing lenalido-
mide, thalidomide, or bortezomib, or a combina-
tion of the three (Table 1).
Time to Progression and Overall Survival
The study was unblinded on December 17, 2009, 
after a median follow-up of 18 months, when 47 of 
the 231 patients in the lenalidomide group (20%) 
as compared with 101 of the 229 patients in the 
placebo group (44%) had progressive disease or 
had died (P<0.001). The hazard ratio for the risk 
of progression or death from any cause was 0.37 
(95% confidence interval [CI], 0.26 to 0.53), indi-
cating a 63% reduction in the risk of progressive 
disease or death among patients in the lenalido-
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mide group. The median time to progression was 
39 months among patients in the lenalidomide 
group and 21 months among patients in the pla-
cebo group (P<0.001) (Fig. S2a in the Supplemen-
tary Appendix). As of December 17, 2009, a total of 
13 of the 231 patients in the lenalidomide group 
(6%) and 24 of the 229 patients in the placebo 
group (10%) had died (hazard ratio, 0.52; 95% 
CI, 0.26 to 1.02; two-sided P = 0.05). The median 
overall survival had not been reached for either 
group (Fig. S2b in the Supplementary Appendix). 
The primary end point (time to progression) was 
met, and the study was unblinded so that pa-
tients in the placebo group could cross over to 
lenalidomide therapy. Of 128 eligible patients 
without disease progression in the placebo group, 
86 received lenalidomide therapy.
The median follow-up as of October 31, 2011, 
was 34 months. Eighty-six of the 231 patients in 
the lenalidomide group (37%) as compared with 
132 of the 229 patients in the placebo group (58%) 
had disease progression or had died (hazard ratio, 
0.48; 95% CI, 0.36 to 0.63). The median time to 
progression was 46 months in the lenalidomide 
group and 27 months in the placebo group 
(P<0.001) (Fig. 1A). The 3-year rate of freedom 
from progression or death was 66% (95% CI, 
59 to 73) among patients in the lenalidomide 
group and 39% (95% CI, 33 to 48) among patients 
in the placebo group. A total of 35 patients who 
received lenalidomide (15%) and 53 patients who 
received placebo (23%) died (two-sided P = 0.03). 
Thus, 85% of the patients in the lenalidomide 
group and 77% of the patients in the placebo 
group were alive at the time of the analysis. The 
rate of overall survival at 3 years was 88% (95% CI, 
84 to 93) among patients in the lenalidomide 
group and 80% (95% CI, 74 to 86) among pa-
tients in the placebo group (hazard ratio, 0.62; 
95% CI, 0.40 to 0.95) (Fig. 1B).
Time to Progression According to 
Stratification at Randomization
Time to progression according to the β2-micro-
globulin level at registration (normal vs. elevated) 
is shown in Figure S2c in the Supplementary Ap-
pendix. Figure S2d in the Supplementary Appendix 
shows time to progression according to status with 
respect to prior induction therapy with thalidomide 
(yes vs. no), and Figure S2e in the Supplementary 
Appendix shows time to progression according 
to status with respect to prior induction therapy 
with lenalidomide (yes vs. no). Figure 2A shows a 
forest plot comparing the relative influence of strat-
ification factors on time to progression. There was 
a trend toward a greater difference in time to pro-
gression with lenalidomide than with placebo for 
status with respect to lenalidomide induction ther-
apy (P = 0.06 for interaction).
Time to Progression According to Response 
at Randomization
Table 1 shows the responses of the patients to au-
tologous hematopoietic stem-cell transplantation 
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Figure 1. Kaplan–Meier Estimates of Progression-free and Overall Survival.
HSCT denotes hematopoietic stem-cell transplantation.
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ing to the response at randomization is shown for 
the analysis of data at the time of unblinding and 
for the later analysis in Figures S2f and S2g in the 
Supplementary Appendix, respectively. Figure 2A 
shows a forest plot comparing the relative influence 
of responses to induction therapy and transplan-
tation and random assignment to lenalidomide or 
placebo on the time to progression in the two 
study groups. We cannot conclude that there was 
an interaction between remission status at random-
ization and maintenance therapy with respect to 
time to progression (P = 0.38). However, lenalido-
mide maintenance therapy appeared to increase 
the time to progression in patients who did not 
have complete remission at day 100 after trans-
plantation.
Overall Survival According to Stratification 
at Randomization
Figure S2h in the Supplementary Appendix shows 
overall survival according to the β2-microglobulin 
level at randomization (normal vs. elevated). Fig-
ure S2i in the Supplementary Appendix shows 
overall survival according to status with respect 
to prior induction therapy with thalidomide (yes 
vs. no), and Figure S2j in the Supplementary Ap-
pendix shows overall survival according to status 
with respect to prior induction therapy with le-
nalidomide (yes vs. no). Overall survival did not 
differ significantly between the lenalidomide 
and placebo groups when they were stratified ac-
cording to the β2-microglobulin level and status 
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Figure 2. Forest Plot of Time to Progression and Overall Survival.
Hazard ratios from subgroup analyses of time to disease progression and overall survival in the randomized population are 
shown (on a natural-log scale). The radii of the circles are proportional to the inverse of the square of the standard error.
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ure 2B shows a forest plot comparing the relative 
influence of responses to induction therapy and 
transplantation and random assignment to le-
nalidomide or placebo on overall survival. The 
data provide evidence that induction therapy with 
lenalidomide was associated with improved over-
all survival in the group that received lenalido-
mide maintenance therapy as compared with the 
placebo group (P = 0.03).
Adverse Events and Second Primary Cancers
Adverse events after randomization (up to Febru-
ary 2012) are summarized in Table 2 and in Tables 
S1 and S2 in the Supplementary Appendix. More 
grade 3 or 4 hematologic adverse events occurred in 
patients in the lenalidomide group than in the pla-
cebo group (P<0.001); in particular, more patients 
in the lenalidomide group had grade 3 or 4 neu-
tropenia. There were no grade 5 hematologic ad-
verse events. There were more grade 3 nonhema-
tologic adverse events in the lenalidomide group 
than in the placebo group (P<0.001); there were no 
significant differences between the groups with re-
spect to the numbers of grade 4 and grade 5 non-
hematologic adverse events.
A total of 23 of 231 patients in the lenalido-
mide group discontinued therapy because of 
adverse events. Two of 143 patients in the pla-
cebo group who did not cross over to lenalido-
mide discontinued therapy because of adverse 
events, and 5 of 86 patients in the placebo group 
who crossed over to lenalidomide discontinued 
therapy because of adverse events (see Fig. S1a 
and S1b in the Supplementary Appendix).
After randomization, 8 new hematologic can-
cers and 10 solid-tumor cancers (excluding non-
melanoma skin cancers) were diagnosed among 
the 231 patients in the lenalidomide group (3.5% 
and 4.3%, respectively). The corresponding num-
bers of new hematologic and solid-tumor cancers 
among the 229 patients in the placebo group were 
1 (0.4%) and 5 (2.2%) (Table 3). The median time 
to the diagnosis of a hematologic cancer after ran-
domization was 28 months (range, 12 to 46) in 
patients in the lenalidomide group, and the 1 he-
matologic cancer that occurred in a patient in the 
placebo group was diagnosed at 30 months. The 
median time to the diagnosis of a solid-tumor 
cancer after randomization was 15 months (range, 
3 to 51) in the lenalidomide group and 21 months 
(range, 6 to 34) in the placebo group. Four of 10 
patients with solid tumors restarted lenalidomide 
after surgery for their second primary cancer. One 
case of a second primary cancer (melanoma) was 
reported in a patient in the placebo group after 
crossover to lenalidomide.
Table 2. Hematologic Adverse Events from Randomization to February 2012.*
Event Lenalidomide (N = 231) Placebo (N = 229) P Value
Grade 3 Grade 4 Grade 3 Grade 4
number of patients (percent)
Neutropenia 74 (32) 30 (13) 27 (12) 7 (3) <0.001
Thrombocytopenia 21 (9) 11 (5) 3 (1) 8 (3) 0.001
Lymphopenia 15 (6) 1 (<1) 3 (1) 1 (<1) 0.01
Anemia 9 (4) 2 (1) 1 (<1) 0 0.006
Leukocytopenia 24 (10) 3 (1) 7 (3) 1 (<1) 0.001
Any event 74 (32) 36 (16) 27 (12) 12 (5) <0.001
* Hematologic adverse events that occurred five or more times in either study group as of February 2012 are listed. For 
patients with multiple adverse events, the event with the highest grade is listed. There were no grade 5 hematologic  
adverse events in either group. Adverse events were graded according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events, version 3.0. As of December 2009, grade 3, 4, or 5 neutropenia had occurred in 64 
patients (28%), 24 patients (10%), and no patients in the lenalidomide group and in 14 patients (6%), 4 patients (2%), 
and no patients in the placebo group, respectively. Grade 3, 4, or 5 thrombocytopenia had occurred in 17 patients (7%), 
10 patients (4%), and no patients in the lenalidomide group and in 1 patient (<1%), 7 patients (3%), and no patients in 
the placebo group, respectively. Grade 3, 4, or 5 lymphopenia had occurred in 11 patients (5%), 5 patients (2%), and no 
patients in the lenalidomide group and in 1 patient (<1%), 1 patient (<1%), and no patients in the placebo group, re-
spectively. Grade 3, 4, or 5 anemia had occurred in 8 patients (3%), 1 patient (<1%), and no patients in the lenalido-
mide group and in 1 patient (<1%), no patients, and no patients in the placebo group, respectively.
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Event-Free Survival and Cumulative Incidence 
of Disease Progression, Second Primary 
Cancers, and Deaths
Event-free survival was a post hoc end point to as-
sess the influence of second primary cancers on 
the observed time to progression and overall sur-
vival. Cases of nonmelanoma skin cancer (all lo-
cal, without distant spread) were not classified as 
second primary cancers in the analysis. As of Oc-
tober 31, 2011, a total of 92 of the 231 patients in 
the lenalidomide group (40%) as compared with 
133 of the 229 patients in the placebo group (58%) 
had progressive disease, had died, or had received 
a diagnosis of a second primary cancer (P<0.001). 
The estimated hazard ratio was 0.53 (95% CI, 0.41 
to 0.69), indicating a 47% reduction in risk among 
patients in the lenalidomide group. The median 
event-free survival was 43 months among patients 
in the lenalidomide group and 27 months among 
patients in the placebo group (Fig. S2k in the Sup-
plementary Appendix). To further assess the cause-
specific risk profiles, we estimated the cumulative 
incidence risks of a second primary cancer, disease 
progression, and death, stratified according to 
group. The cumulative incidence of a second pri-
mary cancer was higher among patients in the le-
nalidomide group than among patients in the pla-
cebo group (P = 0.008). The cumulative incidence of 
progressive disease and the cumulative incidence 
of death were higher among patients in the placebo 
group than among patients in the lenalidomide 
group (P<0.001 and P = 0.002, respectively) (Fig. 3).
Discussion
Although a cure for multiple myeloma is still not 
possible in most patients, maintenance of a pro-
longed progression-free interval with minimal tox-
icity is an important goal in the management of 
this disease. The median overall survival among 
patients who required therapy before 1996 was ap-
proximately 3 years.23 In the era of new agents and 
autologous hematopoietic stem-cell transplanta-
tion, the median overall survival after transplan-
tation is close to 8 years.23,24 In this study, 85% of 
patients in the lenalidomide group and 77% of pa-
tients in the placebo group were alive at a median 
follow-up of nearly 3 years.
Several strategies have been implemented to 
improve the response to primary therapy since it 
correlates with the outcome.25­27 Patients with 
multiple myeloma who have complete remission 
after primary therapy appear to have a longer time 
to progression, resulting in prolonged overall 
survival, although patients with a very good par-
tial response (>90% reduction in myeloma pro-
tein) may have excellent outcomes.25 Maintenance 
of disease control without clinically significant 
progression and dose-limiting toxic effects, as 
well as tolerability for the patient, may also trans-
late into prolonged overall survival. Lenalidomide 
maintenance may increase the time to progres-
sion in patients who do not have complete remis-
sion after induction therapy and transplantation, 
thus generating outcomes similar to those for 
patients with complete remission. Although the 
response criteria of the International Myeloma 
Working Group were not used for all patients in 








Acute lymphoblastic leukemia 1 0
Acute myeloid leukemia 5 0
Hodgkin’s lymphoma 1 0
Myelodysplastic syndrome 1 0
Non-Hodgkin’s lymphoma 0 1
Total 8 1
Solid-tumor cancers
Breast cancer 3 0
Carcinoid tumor 0 1
Central nervous system cancer 1 0
Gastrointestinal cancer 2 1
Gynecologic cancer 1 1
Malignant melanoma 1 2
Prostate cancer 1 0
Thyroid cancer 1 0
Total 10 5
Basal-cell carcinoma 2 1
Squamous-cell carcinoma 2 2
* Four of the eight patients with a hematologic cancer in the lenalidomide 
group received induction therapy with an anthracycline. One solid-tumor can-
cer occurred in a patient with breast cancer in the lenalidomide group. This 
patient had primary breast cancer 26 years before presentation with metastatic 
disease. It is not known whether this breast cancer was a new primary cancer 
or a recurrence of the original breast cancer. Two cases of solid tumors (one 
in the lenalidomide group and one in the placebo group) occurred after disease 
progression. These cases were not included in the analysis of second primary 
cancers, since they occurred after disease progression and then further therapy. 
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this study, the results are consistent with those 
of previous studies with respect to response and 
outcome.
Diagnostic cytogenetic abnormalities in multi-
ple myeloma have been associated with the out-
come.28 Cytogenetic analysis was not required for 
enrollment in this study; however, a review of avail-
able data is ongoing. We expect this information 
to better define populations that would benefit 
most from lenalidomide maintenance therapy. Pa-
tients with disease progression before day 100 af-
ter autologous hematopoietic stem-cell transplan-
tation (4% of the patients who were registered in 
our study) were not eligible to undergo randomiza-
tion. We cannot conclusively say whether induction 
regimens with multiple drugs could overcome pro-
gressive disease and whether this group of patients 
would benefit from maintenance therapy after 
transplantation.
Consolidation therapy after induction therapy 
and transplantation is one strategy that improves 
outcomes. Consolidation appears to be most ef-
fective in inducing complete remission in patients 
with residual disease.29,30 Consolidation therapy 
is more intensive than maintenance therapy, often 
with toxic effects. In this study, lenalidomide 
maintenance as a form of prolonged therapy, as 
compared with placebo, prolonged the time to 
progression and increased overall survival.
Despite its demonstrated efficacy, thalidomide 
maintenance therapy has been limited by neuro-
toxicity, with up to 75% of patients discontinuing 
maintenance therapy.7­12 Other studies have shown 
that lenalidomide and bortezomib used as mainte-
nance therapy are better tolerated, with clinically 
significant efficacy for long-term maintenance af-
ter autologous hematopoietic stem-cell transplan-
tation.31,32 In this issue of the Journal, Attal et al.33 
also report a significantly prolonged time to dis-
ease progression with lenalidomide maintenance 
therapy after autologous hematopoietic stem-cell 
transplantation. A related article by Palumbo et 
al.34 describes a significantly prolonged time to 
disease progression with lenalidomide mainte-
nance therapy after the use of low-dose induction 
therapy. These three studies show the usefulness 
of lenalidomide maintenance therapy for prolong-
ing the time to disease progression in both pa-
tients who have undergone stem-cell transplan-
tation and those who have not. The study reported 
by Attal et al.33 did not show an overall survival 
benefit, a finding that could be due to differ-
ences in induction (use or nonuse of lenalido-
mide-based induction therapy) and consolidation 
(use or nonuse of more alkylator-based chemo-
therapy) before transplantation, the use of lenalid-
omide consolidation therapy in both groups after 
transplantation, the use of two transplantations 
in some patients, and the discontinuation of main-
tenance therapy.33 Longer follow-up and addi-
tional studies may clarify the different findings.
A major concern during maintenance therapy is 
toxicity that limits long-term use and the ability 
to receive future treatment after disease progres-
sion or that results in life-threatening disorders. 
Acute myeloid leukemia or the myelodysplastic 
syndrome has been reported in patients with mul-
tiple myeloma who did not undergo transplanta-
tion and were treated with melphalan.35,36 An 
observational bias is unlikely to explain these find-
ings because of the rapid development of acute 
myeloid leukemia and, to a lesser extent, the my-
elodysplastic syndrome. A recent report by the 
Swedish Cancer Registry described an increased 
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Figure 3. Cumulative Incidence of Second Primary Cancers, Disease 
Progression, and Death in the Lenalidomide and Placebo Groups after  
Randomization.
The cumulative incidence risk of second primary cancers was greater in the 
lenalidomide group than in the placebo group (P = 0.0008). The cumulative 
incidence risks of progressive disease and death were greater in the placebo 
group (P<0.001 for progression and P = 0.002 for death). All P values are 
two-sided.
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tiple myeloma and monoclonal gammopathy of 
undetermined significance (MGUS).37 The find-
ing that acute myeloid leukemia or the myelodys-
plastic syndrome occurs in untreated patients 
with MGUS suggests that these plasma-cell disor-
ders are associated with a hematopoietic stem-
cell or microenvironmental defect in addition to 
an effect of chemotherapy exposure. Multiple 
myeloma is also associated with solid-tumor can-
cers.38 In this study, the increase in second pri-
mary solid-tumor cancers in the lenalidomide 
group was not associated with a specific tumor 
type, and the cause was uncertain. Close monitor-
ing of blood counts, as indicated by the study 
guidelines, and standard screening for cancers 
are recommended.
In conclusion, this study suggests that lenalid-
omide maintenance therapy until disease progres-
sion is feasible for prolonged administration. The 
increase in time to progression led to early study 
unblinding, and despite the crossover, benefits 
with respect to progression and overall survival 
were seen in patients receiving lenalidomide main-
tenance therapy, especially those who had received 
lenalidomide-based induction therapy. It remains 
to be determined whether the incorporation of 
other new agents with lenalidomide will further 
increase the time to disease progression and 
overall survival.
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